肝细胞肝癌 , 生长抑素受体 , 预后

Objects To analyze the expression of somatostatin receptor（SSTR）-2/5 in HBV-relatedhepatocellular carcinomas（HCC）and compare its clinicopathological features and follow-up data. Methods 22patients diagnosed with HCC between February 2008 and July 2010 underwent radical liver resection. Expression ofSSTR-2/5 in HCC and adjacent cirrhotic tissues were examined by immunohistochemistry and real time polymerasechain reaction（PCR）. Moreover，the relationship between SSTR expression and clinicopathological features werealso compared. The patients had routine follow-up exams until cancer reoccurred. Results Adjacent cirrhoticliver and HCC expressed SSTR-2/5. Compared to adjacent cirrhotic liver tissues，expression of SSTR-2/5 in tumorswere significantly lower〔SSTR-2 mRNA（RQ）：1.89±0.74 vs. 2.54±0.80，SSTR-5 mRNA（RQ）：3.61±1.66vs. 6.78±4.27 ；SSTR-2 protein ：68.2%（12/22）vs. 95.5%（21/22），SSTR-2/5 protein ：both 95.5%（21/22），all P＜0.05〕. The mean progression free survival for all patients was 27.3 months. The high SSTR-2/5 expressiongroup had significantly improved the progression free survival compared to the low expression group（log-rank＝4.08，P＝0.043）. Conclusions Down regulation of SSTR transcription may result in loss of a tumor suppressive.Characterization of SSTR expression can be used as a useful parameter to evaluate the prognosis of HCC.

Hepatocellular carcinomas, Somatostatin receptor, Prognosis